Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,384,446 papers from all fields of science
Search
Sign In
Create Free Account
SCH-58500
Known as:
ACN53
, Recombinant Adenovirus-p53 SCH-58500
, SCH 58500
A genetically-engineered adenovirus that contains the gene that encodes the human tumor-suppressor protein p53 with potential antineoplastic activity…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Recombinant Adenovirus-p53
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial
I. Atencio
,
M. Grace
,
+12 authors
R. Warren
Cancer Gene Therapy
2006
Corpus ID: 19704540
The major focus of intrahepatic arterial (IHA) administration of adenoviruses (Ad) has been on safety. Currently, there is little…
Expand
Highly Cited
2003
Highly Cited
2003
Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer
S. Wen
,
V. Mahavni
,
+10 authors
R. Buller
Cancer Gene Therapy
2003
Corpus ID: 24035576
A cohort study was designed to evaluate the efficiency of gene transfer and whether biological activity from the expressed…
Expand
Highly Cited
2002
Highly Cited
2002
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500
R. Buller
,
M. Shahin
,
+7 authors
M. Pegram
Cancer Gene Therapy
2002
Corpus ID: 11628085
Objective: We have previously reported the safety, efficient gene transfer, and favorable CA125 responses of individuals with…
Expand
2002
2002
Porcine Toxicology Studies of SCH 58500, an Adenoviral Vector for the p53 Gene
R. Morrissey
,
C. Horvath
,
+4 authors
J. MacDonald
Toxicological Sciences
2002
Corpus ID: 24311235
Abstract Adenoviral vectors are being actively investigated for their potential utility in gene therapy. SCH 58500, a replication…
Expand
2002
2002
EFFICACY OF ADENOVIRAL P 53 DELIVERY WITH SCH 58500 IN THE INTRACRANIAL 9 L AND RG 2 MODELS
G. Bowers
,
Ju He
,
K. Schulz
,
Gregory Olivarria
,
D. Maneval
,
J. Olson
2002
Corpus ID: 41604951
1. Abstract 2. Introduction 3. Materials and Methods 3.1. Cell Lines 3.2. Tumor Implantation 3.3. Viral Vectors 3.4…
Expand
2002
2002
Intravesical instillation of SCH 58500 transfers p53 in bladder cancer
2002
Corpus ID: 195147036
2000
2000
NK cells mediate the anti-tumor effects of E1-deleted, type 5 adenovirus in a human tumor xenograft model.
L. Nielsen
Oncology Report
2000
Corpus ID: 45467511
SCH58500 (ACN53) is a recombinant adenovirus expressing human p53 for gene therapy of cancer. In preclinical studies, SCH58500…
Expand
2000
2000
Combination therapy with SCH58500 (p53 adenovirus) and cyclophosphamide in preclinical cancer models.
L. Nielsen
Oncology Report
2000
Corpus ID: 34054249
SCH58500 (ACN53) is a replication-deficient, recombinant adenovirus which expresses human p53 tumor suppressor. In preclinical…
Expand
Review
2000
Review
2000
Technology evaluation: Sch-58500, Canji.
Dale L. Barnard
Current opinion in molecular therapeutics (Print)
2000
Corpus ID: 10566107
Sch-58500 is a gene therapy utilizing the p53 gene and is under development by Canji and Schering-Plough for the potential…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE